

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 JANUARY 2013—ERRATA

(1) This Erratum corrects the entry in the 1 January 2013 PBS Schedule for Nicorette and Nicabate P nicotine transdermal patches (item codes 9198D and 5465P). The Schedule entry should appear as shown below.

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Maximum Recordable Value for Safety Net	Brand Name	Manufacturer
	<p>NICOTINE <u>Authority required</u> Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy</p> <p><u>Note</u> Only 2 courses of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised. Benefit is improved if used in conjunction with a comprehensive support and counselling program.</p> <p><u>Authority required</u> Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program. Details of the program must be specified in the initial authority application</p> <p><u>Note</u> A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised.</p> <p><u>Authority required</u> Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested. Details of the program must be specified in the initial authority application</p> <p><u>Note</u> A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised.</p>							
9198D NP	NICOTINE Transdermal patch releasing approximately 15 mg per 16 hours, 28	1	2	..	55.32	36.10	Nicorette Patch	JT
5465P NP	nicotine 21 mg/24 hours patch, 28	1	2	..	55.32	36.10	Nicabate P	GC

(2) This Erratum corrects the entry in the 1 January 2013 Schedule for Olanzapine.

The following Note should appear in the Schedule entry for all Olanzapine items. The Note has been inadvertently omitted for items 1024X, 1037N, 1041T, 1042W, 3381Y, 3382B, 3384D, and 3385E.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

(3) This Erratum corrects the entry in the 1 January 2013 Schedule for VitA-POS eye ointment 5 g (item codes 2167C, 2202X and 2222Y).

The listing for items 2167C, 2202X and 2222Y incorrectly shows “PARAFFIN + RETINYL PALMITATE” as the drug name. The correct drug name for these items is “PARAFFIN”.

(4) This Erratum corrects the entry in the 1 January 2013 Schedule for Tocilizumab.

The Notes with the heading “TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS” and with the subheadings:

- (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.
- (2) Swapping therapy.
- (3) Baseline measurements to determine response.

are not relevant to the section 100 Highly Specialised Drugs listing of Tocilizumab for systemic juvenile idiopathic arthritis. These Notes do not apply to the PBS availability of items 1423X, 1464C, 1419Q, 1481Y, 1482B and 1476Q.

(5) This erratum corrects the Dispensed Price for Max Quantity for entries in the 1 January 2013 Schedule of Pharmaceutical Benefits for brands containing **RISEDRONATE**.

The amendments are required following a court order made on 6 December 2012.

The pbs.gov.au website will reflect the corrected prices from 1 January 2013.

The Dispensed Price for Max Quantity for all listings containing **RISEDRONATE** is amended as set out below:

Name, Restriction, Manner of Administration and Form	Item Code	DPMQ
risedronate sodium 30 mg tablet, 28	8482K	\$259.89
risedronate sodium 35 mg tablet, 4	8621R	\$46.65
risedronate sodium 5 mg tablet, 28	8481J	\$46.65
risedronate sodium 150 mg tablet, 1	9391G	\$49.63
RISEDRONATE SODIUM Tablet 35 mg (enteric coated), 4	8972F	\$46.65
risedronate sodium 35 mg tablet, 4	4444X (RPBS)	\$46.65
risedronate sodium 5 mg tablet, 28	4443W (RPBS)	\$46.65
RISEDRONATE SODIUM Tablet 35 mg (enteric coated), 4	2191H (RPBS)	\$46.65